AEROSURF is the company’s treatment for preterm infants with respiratory distress syndrome and may have other applications. The company signed the new licensing agreement with Lee’s Pharmaceutical and its affiliate, Zhaoke Pharmaceutical.
The licensing agreement allows for the development and commercialization of AEROSURF for any potential indications and applications. The deal will have the two companies handling all the funding for the development and sale of the treatment.
Windtree Therapeutics benefits from this deal thanks to milestone payments and potential royalty payments included in the agreement. The company can receive up to $78.9 million in milestone payments as well as “potential double-digit royalties.”
President and CEO Craig Fraser said the following in a news release:
‘The out-licensing of the KL4 platform supports our portfolio prioritization and increases non-dilutive resources to progressing istaroxime on the significant opportunity in the major markets of cardiogenic shock and heart failure where recent positive data has created what we believe could be a relatively fast and less expensive developmental pathway in cardiogenic shock.”
Today’s news brings heavy trading to WINT stock. As of this writing, more than 52 million shares have changed hands. That’s a jump from the daily average trading volume of about 229,000 shares.
WINT stock is up more than 47% as of Tuesday afternoon.
There’s more hot stock news worth diving into below!
InvestorPlace has all of that news ready to go for traders! This includes why shares of AMC Entertainment (NYSE:AMC), Helius Medical (NASDAQ:HSDT) and Twitter (NYSE:TWTR) stock are moving today. You can find out more at the links below!
More Tuesday Stock Market News
- MoviePass Is Coming Back to Theaters. What Does That Mean for AMC Stock?
- What Is Going on With Helius Medical (HSDT) Stock Today?
- Twitter Whistleblower Sinks TWTR Stock
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.